Regulatory FDA approves Enhertu for two HER2-positive early breast cancer indications Pharmaceutical TechnologyThe FDA has approved Daiichi Sankyo and AstraZeneca's Enhertu for two new indications in HER2-positive early breast cancer.OncologyRead full story pharminent May 18, 2026 (Last updated: May 18, 2026) Pharmaceutical Technology The FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for two new indications in HER2-positive early breast cancer. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Arna Pharma and Slate Run complete JV for new US companyNext: Cellbxhealth partners with AdventHealth on CTCbased monitoring in two major cancer studies Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
